Perioperative Nutrition Optimization for Reducing Complications After Surgical Fracture Fixation (NCT07155447) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Perioperative Nutrition Optimization for Reducing Complications After Surgical Fracture Fixation
1,000 participantsStarted 2026-06-01
Plain-language summary
The objective of this multi-center, prospective, placebo-controlled, randomized study is to compare oral conditionally essential amino acid (CEAA) supplementation for decreasing the key postoperative complications of fracture-related infection, fracture nonunion, and skeletal muscle wasting with a placebo control (PC) after lower extremity fracture fixation. Investigators hypothesize that perioperative oral supplementation with an investigational CEAA supplement (ICS) will reduce postoperative fracture-related infections, fracture nonunion rates, and skeletal muscle wasting in patients with traumatic lower extremity fractures. This is supported by strong pilot data. Conducting a randomized controlled trial at five civilian tertiary referral centers and one military treatment facility will further study the potential benefits of oral CEAA supplementation for preventing the stated key postoperative complications in patients following high energy lower extremity orthopedic trauma. This low cost, low risk intervention has demonstrated potential to expedite Warfighter return to duty as well as potentially reducing delayed limb amputations and mortality in severely injured patients.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adults age 18-55 years
✓. Open or closed fracture of the lower extremity including femur, tibia and/or fibula, calcaneus, talus, Lisfranc joint (OTA/AO 31, 32, 33, 41, 42, 43, 44, 4F, 81, 82, 83, 85)
✓. Ability to begin supplementation within 72 hours of injury
Exclusion criteria
✕. BMI \<18.5 kg/m 2 (underweight) or BMI \> 45 kg/m 2 (severe obesity) to exclude patients with severely increased baseline risk of adverse outcome due to preoperative poor nutrition
✕. Non-ambulatory prior to injury
✕. Currently pregnant
✕. Medical contraindication to CEAA supplementation (e.g., phenylketonuria)
✕. Inability to provide informed consent due to intellectual disability
✕. Protected populations (e.g., prisoners)
✕. Inability to follow up (e.g., homeless at time of surgery, home address out of state of treating facility)
What they're measuring
1
Compare clinical benefit of oral supplementation with CEAA versus a placebo for reducing fracture-related infection after lower extremity fracture fixation.